Pluristem Therapeutics (PSTI) completes enrollment for a Phase I/II study of its Placental...

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

Pluristem Therapeutics (PSTI) completes enrollment for a Phase I/II study of its Placental Expanded (PLX-PAD) cells for the treatment of muscles traumatized during hip-replacement surgery. "This trial is important as it marks the first time PLX-PAD cells have been used in patients following surgically induced muscle trauma. It also provides data on the potential use of PLX cells for the treatment of sports related injuries," says Pluristem. (PR)